MétaCan
Menu
Back to cohort
Record W4385704144 · doi:10.1016/j.ibneur.2023.08.001

Corrigendum to “Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study” [IBRO Neurosci. Rep. 15 (2023), pp. 90–99]

2023· erratum· en· W4385704144 on OpenAlex

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.

Bibliographic record

VenueIBRO Neuroscience Reports · 2023
Typeerratum
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicMuscle Physiology and Disorders
Canadian institutionsThunder Bay Regional Health Sciences Centre
Fundersnot available
KeywordsMuscular dystrophyDuchenne muscular dystrophyMedicineCongenital muscular dystrophyInternal medicine

Abstract

fetched live from OpenAlex

The authors regret that the last section of Table 2 was missing from the published version. The correct table has been included below with the missing section highlighted in red text.Table 2Demographics and baseline characteristics.Control Steroid -veSubjectAge in yearsWeight in kgsExon DeletionClinical DiagnosisAmbulatory/ Non-AmbulatoryDose of Deflazacort (mg/day)Duration of consumption of steroids16–101210 & 11Duchenne Muscular Dystrophy (DMD)AmbulatoryNANA26–102746–55Duchenne Muscular Dystrophy (DMD)Non-AmbulatoryNANA316–2048Duchenne Muscular Dystrophy (DMD)AmbulatoryNANA411–15608–48Duchenne Muscular Dystrophy (DMD)Non-AmbulatoryNANA511–155510–11/DupDuchenne Muscular Dystrophy (DMD)Non-AmbulatoryNANAControl Steroid +ve116–206544Duchenne Muscular Dystrophy (DMD)Non-Ambulatory68 years26–10255 & 6Duchenne Muscular Dystrophy (DMD)Ambulatory122.5 months36–102149–52Duchenne Muscular Dystrophy (DMD)Ambulatory911 months411–154852Duchenne Muscular Dystrophy (DMD)Ambulatory66 yearsN-163 Steroid -ve16–102848–50Duchenne Muscular Dystrophy (DMD)AmbulatoryNANA21–51045–50Duchenne Muscular Dystrophy (DMD)AmbulatoryNANA311–153845–50Duchenne Muscular Dystrophy (DMD)AmbulatoryNANA46–104560Becker muscular dystrophy (BMD)AmbulatoryNANA56–103910–11/ DupDuchenne Muscular Dystrophy (DMD)Non-AmbulatoryNANA66–102149–52Duchenne Muscular Dystrophy (DMD)AmbulatoryNANA711–153943Duchenne Muscular Dystrophy (DMD)Non-AmbulatoryNANA811–1540Duchenne Muscular Dystrophy (DMD)Non-AmbulatoryNANA96–102244–57/DupDuchenne Muscular Dystrophy (DMD)AmbulatoryNANAN-163 Steroid +ve11–51848–50Duchenne Muscular Dystrophy (DMD)Non-Ambulatory65 months211–155917Duchenne Muscular Dystrophy (DMD)Ambulatory62 months311–154060Becker muscular dystrophy (BMD)Ambulatory66 years46–102048–52Duchenne Muscular Dystrophy (DMD)Ambulatory63 years56–103648–50Duchenne Muscular Dystrophy (DMD)Ambulatory63 years611–155818–29Duchenne Muscular Dystrophy (DMD)Non-Ambulatory66 years76–102248–52Duchenne Muscular Dystrophy (DMD)Ambulatory32 years811–153648–52Duchenne Muscular Dystrophy (DMD)Non-Ambulatory65 years911–152906–07Duchenne Muscular Dystrophy (DMD)Ambulatory62 months Open table in a new tab The authors would like to apologise for any inconvenience caused. DOI of original article: https://doi.org/10.1016/j.ibneur.2023.06.007. Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical studyIBRO Neuroscience ReportsVol. 15PreviewThis exploratory case-control study is to evaluate the effects of supplementation of Aureobasidium pullulans-N-163 strain produced 1,3–1,− 6 beta glucan in young patients with Duchenne muscular dystrophy (DMD). Full-Text PDF Open Access

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.007
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.661
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.007
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.000
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0020.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.033
GPT teacher head0.318
Teacher spread0.284 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it